NP Rank:
Medivation And Pfizer Faced With Dimebon Efficacy Failure
Medivation stock plummets as Dimebon found ineffective.
Pharmaceutical company Medivation (MDVN) is experiencing a severe stock drop in the wake of the news that its experimental drug Dimebon (or latrepirdine) used for the treatment of Alzheimer disease does not show significant efficacy. The consequences of failed trials are:
- stock drop of 67%
- fallback in drug treatment of Alzheimer's disease
The investigative anti-Alzheimer's treatment developed by Medivation and Pfizer failed to meet "efficacy endpoints" in late-stage phase 3 trials. Moreover, no statistically significant improvements relative to placebo were achieved on the co-primary endpoints. The efficacy of the drug was measured by cognition and global function. Dimebon was a promising drug that had the potential to improve symptoms in Alzheimer stricken patients.
Medivation reacted in a statement, saying it will review the efficacy data with Pfeizer to determine the future of the drug.
"We are evaluating the CONNECTION data with Medivation. After that review, Pfizer will be in a position to determine appropriate next steps regarding the dimebon program," said Dr. Briggs W. Morrison, senior vice president, clinical development, Primary Care Business Unit at Pfizer.



Most RecentMost Recommended Comments (2)
at 17:43 on March 3rd, 2010
An interesting story.
at 11:35 on March 7th, 2010
It is not only Russian studies you have to cast a cold eye upon. What about the Edward Tobinick Studies www.nrimed.com/index.html Not bad for a Los Angeles dermatologist with a practice he calls Institute of Laser Medicine which also doubles as Institute for Neurological Research. Alzheimer's, Disc-related disease, metastatic Cancer, SARS, no problem. Tobinick has managed to make extraordinary claims in the off-label use of an anti-TNF biologic therapy for rheumatoid arthritis - etanercept (Enbrel) for all these chronic conditions and some more, but it does not stop there. Tobinick claims to have invented two unique procedures (which he claims patent rights) in the novel administration of his treatment. Has Tobinick over these last ten years ever provided one piece of data for independent scrutiny; the answer is NO! While you digest these facts, there are Alzheimer's families seeking out Tobinick at his clinics, there are Alzheimer's families seeking out Medical Doctors, who have signed up with Tobinick, and for a fee and royalty, provide 'The Tobinick Method' off-label etanercept (Enbrel)administration to desperate Alzheimer's patients. If you want a medical ponzi scheme, I volunteer Tobinick's Alzheimer's claims. Let me guide you to Tobinick's pre Alzheimer's claims, when he put all his talent with off-label use of etanercept (Enbrel) for disc-related disease, which he patented as 'DiskCure' . Tobinick early on, learned the persusive qualities of creating his own 'testimonial videos' depicting 'real life' people and their experiences after Tobinick's etanercept treatment. This real 'testimonial video' is one of my favorites. www.discpainbreakthrough.com/videos.html The title: Video 7: Rapid relief for an orthopedic surgeon following the patented perispinal etanercept treatment at the INR. Tobinick created video claims this is an Orthopedic Surgeon......this is beyond absurdity.